With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.
There is some debate among Russian legal professionals about whether “selection inventions” are considered patentable, but the answer seems clear, says Valery Djermakian of Gorodissky & Partners.
‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados.
The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker.
The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins.
In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson.
In September 2016, the Francis Crick Institute opened the doors to its multimillion-pound new home in London. With a wide range of research being undertaken, LSIPR examines the role of IP and the associated challenges for the organisation.
Dolly the Sheep, which would have been 20 this year, raised the possibility of cloning and forced politicians and IP practitioners to address the ethics of the process, with differing results in the US and the UK, as LSIPR reports.
There is some debate about whether the ‘patent cliff’ or the need to innovate is driving M&A activity in the pharmaceutical industry, where billions of dollars have been spent in the past few years, as LSIPR finds out.
On December 7, LSIPR will be hosting the Life Sciences Patents Network Europe 2016 at the Bloomsbury Hotel in London. Here we preview the main talking points.